NCT03152708Unknown不适用
The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 62
- 主要终点
- CD95 Ligand Positive Rate
研究概览
简要总结
This study was conducted on the post-operative tumor tissues from 62 GBM patients. 20 slices are necessary for all the CD95 and CpG2 test in the central lab by the methods of immunisation and DNA methylation.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chinese nationality
- •No limits on Gender and age
- •First diagnosed GBM
- •Brain tumor tissue cytological diagnosis of glioblastoma (GBM, pleomorphic glioblastoma, WHO level IV)
排除标准
- •Other types of glioma by histological diagnosis
- •Tumor tissue not eligible for the central laboratory testing standard
- •No enough tumor tissue for the central laboratory test
结局指标
主要结局
CD95 Ligand Positive Rate
时间窗: 0 day
次要结局
- CpG2 Positive Rate(0 day)
研究者
相似试验
招募中
不适用
A Study of 68Ga-ABY-025 PET for Non-invasive Quantification of HER2-expression in Advanced Breast CancerHER2-positive Breast CancerNCT03655353Henrik Lindman160
撤回
早期 1 期
Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent GliomaIDH MutationGliomaNCT05061251University of Texas Southwestern Medical Center
已完成
1 期
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination TherapyMetastatic Castration-resistant Prostate CancerColorectal CancerPancreatic CancerMelanomaNon-small Cell Lung CancerBladder CancerHead Neck Squamous Cell CarcinomaProstate CancerOvarian CancerGastric CancerEsophageal CancerNCT04068896NGM Biopharmaceuticals, Inc89
进行中（未招募）
2 期
MIBG Therapy for Patients With MIBG Avid TumorsMIBG Avid TumorsNCT02378428Nationwide Children's Hospital65
招募中
1 期
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid TumorOther Solid TumorsNSCLCNCT05332574Genor Biopharma Co., Ltd.120